Membrane-bound TRAIL-armoring augments CAR-T cells in mesothelin-positive solid malignancies
Background
Mesothelin (MSLN)-targeted chimeric antigen receptor (CAR)-T cell therapy shows an effective and long-lasting response in high MSLN-expressing tumors, but fails to treat tumors with heterogeneous levels of antigen expression. Here we descri…